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Abstract
Background: Epidemiologic evidence supports a role of soy foods in breast cancer etiology.
Because chronic inflammation appears to be a critical component in carcinogenesis, we examined
the potential anti-inflammatory effects of soy foods.
Methods: The original 2-year dietary intervention randomized 220 premenopausal women of
whom 183 women (90 in the intervention group and 93 in the control group) were included in the
current investigation; 40% were of Asian ancestry. The intervention group consumed two daily soy
servings containing 50 mg of isoflavones (aglycone equivalents), whereas the controls maintained
their regular diet. Five serum samples obtained at month 0, 3, 6, 12, and 24 were analyzed for
interleukin (IL)-6, C-reactive protein (CRP), leptin, and adiponectin by ELISA. For statistical
analysis, mixed models were applied to incorporate the repeated measurements.
Results:
The levels of all analytes were lower in Asian than Caucasian women. Overweight women had
significantly higher levels of CRP, IL-6, and leptin and lower levels of adiponectin than normal weight
women. We did not observe a significant effect of soy foods on the four markers, but leptin
increased in the control and not in the intervention group (p = 0.20 for group-time effect); this
difference was significant for Asian (p = 0.01) and obese women (p = 0.005).
Conclusion: During this 2-year intervention, soy foods did not modify serum levels of CRP, IL-6,
leptin, and adiponectin in premenopausal women although leptin levels remained stable among
women in the intervention group who were obese or of Asian ancestry. Further studies with
diverse markers of inflammation are necessary to clarify the specific effect of soy on immune
responses.
Introduction
Isoflavones, weak estrogenic compounds found in high
concentrations in soy beans, have been explored as cancer
preventive agents for a long time [1,2]. A meta-analysis that
described a 15% lower breast cancer risk related to soy [3]
offers fairly strong epidemiologic support for a protective
effect of soy that, however, might be restricted to Asian pop-
ulations [4]. Different hypotheses about the underlying
mechanism of cancer-protective effects of soy have been
evaluated, including antioxidant, antiproliferative proper-
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ties, and the modulation of lipoprotein metabolism, as
well as its estrogenic and antiestrogenic effects [5]. The
results of a 2-year soy intervention at our center [6] and
reports from other trials [7-10] indicate that the preventive
effects of soy on breast cancer risk, if they exist, are not
mediated by their effects on the major circulating sex hor-
mones. On the other hand, results from animal studies and
human trials support the hypothesis that soy or isoflavones
reduce chronic inflammation, a possible risk factor for
breast cancer [11-13]. Circulating inflammatory markers,
such as cell-adhesion molecules and C-reactive protein
(CRP), were decreased in some studies [14,15]. Genistein
appears to down regulate the inflammatory response
through its tyrosine kinase inhibitory effects [16,17].
While the original objective of our randomized trial had
been to examine effects of two daily soy servings on ster-
oid hormones and mammographic densities [6,18], the
aim of the current study was to examine the effects of soy
foods on serum markers of obesity and systemic inflam-
mation, interleukin (IL)-6, IL-2, CRP, leptin, and adi-
ponectin, in premenopausal healthy women. The choice
of markers was driven by the concept of capturing differ-
ent aspects of the immune response through a combina-
tion of cytokine levels as it appears that they predict
disease better than single markers [19]. IL-6 is one of the
major components responsible for the acute phase pro-
tein synthesis by the liver, particularly CRP, a sensitive,
non-specific indicator of inflammation. IL-2 is a growth
factor for antigen-stimulated T lymphocytes, where it
increases cytokine synthesis and B cell proliferation [20].
Leptin, a possible link between nutritional status and the
immune function, is a marker of obesity, participates in
pro-inflammatory responses, and is an important growth
factor for breast cancer [20,21]. Adiponectin is the most
abundant protein in adipocytes with a strong anti-inflam-




As described elsewhere [6], the participants were recruited
by sending out 10,022 invitations to women who had
received a normal screening mammogram. Of these, 975
(9.73%) interested women replied and 352 eligible
women aged 35–46 years were identified during a tele-
phone-screening interview. Women were excluded from
this study due to use of oral contraceptives or other sex
hormones, diagnosis of cancer, hysterectomy, and no
intact ovary or no regular menstrual periods. After a run-
in period, 220 women were randomized to a soy diet or to
the control group and 189 subjects completed 2 years of
intervention [6]. The Institutional Review Boards of the
University of Hawaii approved the study protocol; partic-
ipants signed informed consent and gave written permis-
sion to use frozen samples for future analyses.
Study procedures
This trial was designed to provide two servings of soy per
day containing approximately 25 mg aglycone equiva-
lents of isoflavones per serving [23]. A choice of tofu, soy
milk, roasted soy nuts, soy bars, and soy protein powder
was offered to the participants. The same brands of soy
foods was used throughout the intervention and the iso-
flavone content of food items was monitored by high-
pressure liquid chromatography (HPLC) with photo
diode array detection [24]. Women in the control group
were instructed to maintain their regular diet. Body weight
was recorded at baseline and at each study visit. Adher-
ence to the study protocol was high in both arms of this
study [6,25]. Subjects in the intervention group showed
an increase in self-reported intake of isoflavones from 4.4
mg/day at baseline to 57.3 mg/day as assessed by unan-
nounced 24-hour recalls, which was confirmed by an
increase in urinary isoflavone excretion from 8.0 to 59.8
nmol/mg creatinine. Controls continued their usual soy
intake as confirmed by 24-hour recalls and urinary isofla-
vone excretion.
Serum Sample Collection
This study makes use of existing serum samples that were
collected during the 2-year trial period. We collected
blood samples at baseline as well as 3, 6, 12 and 24
months after randomization timed to occur 4–6 days after
ovulation as determined by an ovulation kit [6]. Blood
was allowed to clot for 30 minutes and centrifuged at
3000 rpm for 15 minutes; aliquoted serum was frozen at
-80°C. Not all women donated five samples because of
dropout or failure to provide a specimen at one point of
the study. We analyzed samples from 183 women, 93 in
the control group and 90 in the intervention group. For
141 women, 5 specimens were available. There were 4
samples available for 37 women and only 3 measure-
ments for 5 women, but each of these women provided a
baseline sample.
Analytical methods
Serum levels of IL-6, IL-2, leptin, and adiponectin were
assessed by double-antibody enzyme-linked-immuno-
sorbend-assay ELISA assays (R&D Systems, Minneapolis,
MN) according to the manufacturer's specifications. Plots
of concentration vs. absorbance for standards were pre-
pared using a four parameter fit and concentrations of
unknown samples extrapolated from the standard curve.
The CRP assay was based on a latex particle enhanced
immunoturbidimetric method using a Cobas MiraPlus
clinical autoanalyser and a kit from Pointe Scientific, Inc,
Lincoln Park, MI. Batches of 30 or 40 samples contained
all 5 samples of each woman and an equal number of
women by group. Detection limits were 0.1 mg/L (CRP),
0.2 pg/mL (IL-6), 0.8 ng/mL (leptin), 1.8 μg/mL (adi-
ponectin) and 31 pg/mL (IL-2). Positive IL-2 values could
only be detected in 6 women and were, therefore, notJournal of Inflammation 2009, 6:9 http://www.journal-inflammation.com/content/6/1/9
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included in the analysis. The assay quality was assessed by
49 blinded controls from a pooled sample donated by 10
premenopausal center employees. The mean intra-batch
coefficients of variation (CV) for CRP, leptin, adiponectin,
and IL-6 were 6.1%, 4.6%, 14.0% and 6.8%, whereas
inter-batch CVs were 18.2%, 9.5%, 24.9% and 17.8%,
respectively. Urinary isoflavone excretion was measured
by HPLC and serum estradiol by radioimmunoassay as
described previously [6].
Statistical Analysis
Statistical analyses were performed using the SAS statistical
software package version 9.1 (SAS Institute, Inc., Cary, NC).
Non-normally distributed data were log-transformed prior
to statistical analysis (see table footnotes for details). To
assess differences in baseline characteristics between the
two groups, Student's t tests were performed for continuous
variables and χ2 tests for categorical variables. We calcu-
lated unadjusted means and standard deviations for each
marker by group and time of blood draw. To assess the cor-
relation of markers, we computed Spearmen correlation
coefficients (rs); to measure stability over time, we calcu-
lated intraclass correlation coefficients (ICC).
To assess the effect of the soy diet on the markers, we exam-
ined overall group mean differences using the Proc Mixed
procedure in SAS 9.1; the repeated measurements were
included as random effect [26,27]. Mixed models address
the dependence of observations in a repeated measurement
design by modeling the within-person and between-person
variances simultaneously. They allow for an analysis of
repeated measures with unbalanced times of measurement;
subjects contribute to the overall model as long as they have
one measurement [28]. We examined the significance of the
dietary intervention, the change over time, and the interac-
tion between group assignment and time. To assess their
possible influence on the intervention, body mass index
(BMI), serum estradiol, and urinary isoflavone excretion
were included as time dependent covariates. Analyses were
repeated for subgroups after stratification by ethnicity (Asian
vs. Caucasian) and BMI (<25, 25–30, and >30 kg/m2).
Results
This study included 67 Caucasians, 49 Japanese, 23 Hawai-
ians, 11 Filipinos, 14 Chinese, and 19 women of mixed and
other ethnicities. Women in the intervention group (n =
90) did not differ significantly from women in the control
group (n = 93) (Table 1). The mean age at baseline was 42.7
years in the intervention and 43.4 years in the control
group (p = 0.21). Body weight at baseline increased in both
groups throughout the trial: 0.8 kg in the diet and 1.2 kg in
the control group (p = 0.53). The weight gain was slightly
higher among Asians than non-Asians (1.4 vs. 0.7 kg; p =
0.27). The mean increase among Asian controls vs. inter-
vention women was 1.1 vs. 1.7 kg (p = 0.46); the respective
values for non-Asians were 0.6 vs. 0.8 kg (p = 0.80).
The ICCs for leptin, CRP, IL-6, and adiponectin based on
all measurements over 2 years were 0.91, 0.65, 0.71, and
0.84, respectively. Although IL-6 and CRP levels were
slightly higher in the control than in the intervention
group, the mean levels at baseline did not vary signifi-
cantly by group; the respective p-values were 0.08 and
0.44. CRP and IL-6 were strongly correlated (rs = 0.54; p <
0.0001). Leptin was also associated with IL-6 (rs = 0.50; p
< 0.0001) and CRP (rs = 0.49; p < 0.0001). We found
inverse correlations of adiponectin with IL-6 (rs = -0.29; p
< 0.0001), CRP (rs = -0.15; p < 0.0001) as well as leptin (rs
= -0.26; p < 0.0001). Mean levels of all analytes were lower
in Asian than Caucasian women at baseline: 1.48 vs. 2.57
mg/l for CRP (p = 0.01); 1.04 vs. 1.32 pg/mL for IL-6 (p =
0.09); 7.52 vs. 8.33 μg/mL for adiponectin (p = 0.17), and
14.8 vs. 22.3 ng/mL for leptin (p = 0.0004). Furthermore,
overweight women (BMI ≥ 25 kg/m2) had significantly
higher levels of CRP (3.4 vs. 1.0; p < 0.0001), IL-6 (1.5 vs.
0.9; p < 0.0001), and leptin (28.3 vs. 10.7; p = 0.001) than
normal weight women, whereas adiponectin was higher
in normal than overweight women (9.2 vs. 6.7; p  <
0.0001).
We did not observe a significant effect of the soy intervention
on any of the analytes (Table 2). The respective p-values for
the interaction between group assignment and time were
0.48 for CRP, 0.51 for IL-6, and 0.71 for adiponectin. How-
ever, a non-significant effect of the soy diet was observed on
leptin levels. While leptin levels were stable in the interven-
tion group, they increased over time from 19.1 ng/mL to
21.0 ng/mL in the control group (p = 0.03 for time, p = 0.20
for group-time interaction and p = 0.43 for group effect).
For IL-6, CRP, and adiponectin, stratification by ethnicity
and BMI did not reveal a significant intervention effect for
any subgroup (data not shown). For leptin, stratified post-
hoc analysis of Asian women showed a significant inter-
vention effect of soy (p  = 0.01) that was not present
among Non-Asians (Table 3). In the Asian controls, leptin
levels rose from 12.6 to 14.7 ng/mL, whereas they
remained stable in the intervention group (17.1 to 16.6
ng/mL). Including BMI as a time dependent variable in
the models did not explain this change; the interaction
effect remained significant (p = 0.006). Similarly, a signif-
icant effect of soy on leptin was observed in obese women
(BMI ≥ 30 kg/m2) (p = 0.005) and could not be explained
but BMI, but not in those with lower BMIs (Table 3). In
the obese group, controls showed an increase in leptin
from 38.7 to 47.6 ng/mL, whereas levels in the interven-
tion group were stable (38.1 and 38.5 ng/mL).
Additional analyses by compliance and age did not sug-
gest an effect in any subgroup. Urinary isoflavone excre-
tion was not related to any of the four markers. However,
serum estrogen levels showed a significant direct associa-
tion with leptin only (p = 0.003). For none of the fourJournal of Inflammation 2009, 6:9 http://www.journal-inflammation.com/content/6/1/9
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markers were the intervention results modified by includ-
ing estradiol or urinary isoflavone excretion into the
mixed models. We also excluded women with CRP levels
>3.0 mg/l, a level that most likely indicates an acute con-
dition, but did not observe an effect of soy.
Discussion
Contrary to our hypothesis, these results do not indicate a gen-
eral intervention effect of a 2-year soy diet on CRP, IL-6, and
adiponectin in premenopausal women. Although the overall
effect was not significant for leptin, we noted that leptin levels
remained stable in the intervention group over 2 years while
they increased by 10% in the control group. This trend was sta-
tistically significant among women with Asian ancestry as well
as in obese subjects. Over 2 years, leptin levels increased by
17% in the Asian controls and by 23% among obese controls,
while levels in the intervention group decreased or remained
stable. The differential effect was not explained by differences
in weight gain and suggests that soy may prevent an increase
in leptin over time due to weight gain. The stability of serum
levels over time indicates the usefulness of these markers as a
tool in epidemiological research.
Previous interventions show conflicting results and were
limited by their short duration and their small sample size.
Our results agree with several studies that report no effect of
soy foods on CRP [13,29-34]. Yet, some reports described
lower CRP levels with soy consumption [35-38]. IL-6 was
measured in four investigations with little indication that
supplementation had an effect [29,34,38,39]. Contrary to
our findings, adiponectin levels increased in a soy interven-
tion study among postmenopausal women [40], but no
studies in premenopausal women have been performed to
our knowledge. Two studies measuring leptin during an
intervention with soy protein isolate reported no change in
leptin levels over 3 months [40,41]. The investigation of
vascular markers of inflammation also resulted in largely
negative findings [13,15,32,38].
Given the multiple comparisons, the significant results for
leptin among obese women could be a chance finding, but
it is possible that soy only has a beneficial effect on these
women due to their abnormally high leptin levels. This
observation would correspond to the finding that soy foods
have a more favorable effect among individuals with high
Table 1: Characteristics of study participants in a 2-year soy trial
Variable Controls Intervention P-value2
Mean [SD] Mean [SD]
Number obf subjects 93 90
Age at randomization (y) 42.7 [3.0] 43.3 [2.9] 0.21
Ethnicity1
Caucasian 35 [37.6%] 32 [35.6%] 0.96
Japanese 24 [25.8%] 25 [27.8%]
Hawaiian 11 [11.8%] 12 [13.3%]
Filipino 7 [7.5%] 4 [4.4%]
Chinese 7 [7.5%] 7 [7.8%]
Mixed/other 9 [9.6%] 10 [11.3%]
Body weight (kg)
At baseline 68.3 [17.5] 67.9 [15.2] 0.87
After 2 y 69.1 [16.1] 69.1 [15.5] 0.99
Change over 2 y 0.8 [4.1] 1.2 [3.6] 0.54
Body mass index (kg/m2)
At baseline 26.1 [6.1] 26.2 [5.4] 0.96
After 2 y 26.4 [6.5] 26.6 [5.5] 0.85
Change over 2 y 0.32 [1.5] 0.45 [1.4] 0.54
Lifetime soy intake (svgs) 2440 [2967] 2044 [2541] 0.33
Soy consumption (svgs/y)1
During early life >0 49 [52.7%] 47 [52.2%] 0.95
During adult life >36 47 [50.5%] 45 [50.0%] 0.94
Lifetime ≥ 27 49 [52.7%] 47 [52.2%] 0.95
Marker levels at baseline
CRP (mg/L) 2.31 [3.28] 1.95 [3.10] 0.44
IL-6 (pg/mL) 1.36 [1.47] 1.06 [0.64] 0.08
Adiponectin (μg/mL) 8.13 [3.68] 7.87 [4.13] 0.65
Leptin (ng/mL) 19.06 [15.78] 19.45 [15.02] 0.87
1 Frequencies and percentages
2 p-values from χ2- and Student's t testJournal of Inflammation 2009, 6:9 http://www.journal-inflammation.com/content/6/1/9
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than normal plasma lipid concentrations [42]. Whereas an
increase in leptin among controls was expected as the result
of the mean 1.2 kg weight gain, the stable levels in the inter-
vention group, which also gained 0.8 kg over the 2 years,
might suggest potential beneficial effects of soy on leptin.
Furthermore, the effect may have been stronger in Asian
women because of their higher percent body fat and their
larger proportion of adipose fat tissue as compared to Cau-
casians [43]. These findings may contribute to the lower
breast cancer risk associated with soy consumption [3], par-
ticularly for Asians [4], through a number of different
mechanisms. As an adipocyte-derived cytokine, leptin acts
pro-inflammatory through induction of cytokines by T cells
[20], but it has also been identified as a growth factor for
breast cancer [21]. It appears to increase estrogen levels by
stimulating aromatase expression, and to activate estrogen
receptors [21], and to induce growth in breast cancer cell
lines and human primary breast carcinoma [44].
A number of reasons may explain the lack of an interven-
tion effect. Due to limits of detection, availability of
serum, and budgetary constraints, we were not able to
measure more markers. The four measured markers, CRP,
IL-6, leptin, and adiponectin, represent only a small sub-
set of inflammatory processes. To assess the overall
immune response and complex secretion and interaction
patterns of cytokines, measuring many more cytokines
would be useful [19]. Our choice of markers was based on
their broad usage, detection levels, and availability of
serum. Another limitation of our study design was that lit-
tle attention was paid to acute infections and the use of
NSAIDs or statins. As to adjustment for body fat, BMI is
not a very representative measure across ethnic groups
[43], but no other information on adiposity was available.
Our study had several strengths. We were able to use exist-
ing serum samples from a 2-year randomized intervention
with excellent compliance [6] to investigate a relatively
novel hypothesis. The serum samples were collected dur-
ing the luteal phase under standardized conditions and
analyzed with highly reproducible results. The long inter-
vention period, the relatively large sample size, and the
availability of multiple samples for each subject were a
great benefit because the study design addressed the
intraindividual variability in inflammatory markers. Also,
traditional soy foods, as in our study, represent the nutri-
tional exposure of habitual soy consumers in Japan in
China with a low breast cancer risk more closely than pro-
tein isolates or isoflavone supplements used in most of
the previous reports.
In contrast to the findings of this soy intervention that did
not observe a change in serum levels of CRP, IL-6, leptin,
and adiponectin during 2 years, experimental findings
[11,12,17] and animal studies [45,46] support an influ-
ence of soy foods on immune responses. If an effect exists,
Table 2: Effects of a 2-year soy trial on serum levels of inflammatory markers1
Marker Time (months) Control Intervention P-values
N Mean SD N Mean SD Group Time Interaction
CRP (mg/L) 0 92 2.3 3.3 90 1.9 3.1
3 84 2.3 3.4 82 1.7 2.8
6 86 2.6 3.7 85 1.8 3.5
12 89 2.2 3.1 86 1.6 2.6
24 85 2.1 3.0 83 2.6 4.5 0.47 0.35 0.48
IL-6 (pg/mL) 0 93 1.4 1.5 90 1.1 0.7
3 84 1.5 1.8 82 1.1 0.5
6 88 1.3 1.0 86 1.2 1.0
12 89 1.3 1.2 86 1.1 0.6
24 85 1.3 1.2 83 1.2 0.9 0.21 0.15 0.51
Adiponectin (μg/mL) 0 93 8.1 3.7 90 7.9 4.1
3 84 8.2 3.5 82 7.8 4.3
6 89 8.4 4.0 86 8.2 4.5
12 89 8.3 4.0 85 7.6 4.0
24 85 8.4 3.9 83 7.9 3.9 0.61 0.88 0.71
Leptin (ng/mL) 0 93 19.1 15.8 90 19.4 15.0
38 4 2 0 . 0 1 7 . 3 8 2 1 9 . 6 1 5 . 2
68 8 2 0 . 7 1 6 . 8 8 6 1 9 . 6 1 4 . 9
12 89 21.1 17.1 86 19.4 14.3
24 85 21.0 18.0 83 19.2 14.9 0.43 0.03 0.20
1Obtained from mixed linear models; log-transformed values were used (except adiponectin) and back-transformed means are presented.Journal of Inflammation 2009, 6:9 http://www.journal-inflammation.com/content/6/1/9
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it is possible that soy protein, n-3 fatty acids, a major com-
ponent of soy beans that may influence immune
responses [47], or other components rather than isofla-
vones are responsible for the biological effects of soy
beans. Despite the overall negative findings of this report,
it is possible that dietary patterns rich in soy food may
have a beneficial effect on markers of obesity and/or
chronic inflammation in specific populations. This
hypothesis deserves further investigation, in particular the
possible link between soy, leptin, and breast cancer.
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